Top Markets
#1 Ontology Gas Ontology Gas +45.07%
#2 Anvil Anvil +19.32%
#3 ETHGas ETHGas +19.07%
#4 Status Status +18.81%
#5 The Black Bull The Black Bull +17.02%
#6 Geodnet Geodnet +16.47%
#7 Fake World Assets Fake World Assets +13.85%
#8 Derive Derive +10.68%
#9 Ontology Ontology +9.78%
#10 Gas Gas +9.27%
Coin of the day
Ontology Gas Ontology Gas
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Classifica tra le azioni #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Prezzo delle azioni
$9.81
Ultima sincronizzazione: 2025-03-18
Capitalizzazione di mercato
$48.68M
Variazione (1 giorno)
1.55%
Variazione (1 anno)
0.00%
Paese
US
Scambia AlloVir, Inc. (ALVR)

Categoria

Healthcare
Rapporto P/B per AlloVir, Inc. (ALVR)
Rapporto P/B al August 2026 TTM: 1.68
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di AlloVir, Inc., il rapporto P/B attuale (TTM) è 1.68. Alla fine del 2023, era pari a 0.00.
Storico del rapporto P/B per AlloVir, Inc. da 2022 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 1.68 320.88%
2024 0.40 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 276.71%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 270.73%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 48.82%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 120.30%
US